Skip to content
Trial Eligibility
Menu

Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation

NCT07908641

This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .

Summary

The main objective of this study is to compare the relative bioavailability, safety, and tolerability of extended-release and immediate-release apremilast formulations in healthy participants.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Psoriasis
  • Arthritis, Psoriatic
  • Oral Ulcer

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1
Ages
18 to 60 years
Sex
All
Healthy volunteers
Accepted
Sponsor
Amgen
Last updated on ClinicalTrials.gov
November 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Florida · 1

  • Fortrea Clinical Research Unit - Daytona Beach · Daytona Beach, FL

Texas · 1

  • Fortrea Clinical Research Unit - Dallas · Dallas, TX

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.